Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRIPO-Study
2024-514255-15-01Phase 4Authorised
- Sponsor
- Erasmus MC
- Start
- Nov 2024
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of alglucosidase alfa, avalglucosidase alfa, olipudase alfa and miglustat in Pompe disease, sponsored by Erasmus MC. Primary endpoints: Efficacy - Muscle strength, Efficacy - Muscle function and 4 more. Planned start Nov 2024; status: authorised.
02
Drugs
alglucosidase alfaavalglucosidase alfaolipudase alfamiglustat
03
Conditions
Pompe disease
Beyond the preview
Go deeper on 2024-514255-15-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514255-15-01.